Not All Sunshine and Santa Claus For Generics Post-Mensing

more+
less-
more+
less-

When the Supreme Court decided Mensing, we imagine generic drug manufacturers felt like Stephen Sondheim’s “Everything’s Coming Up Roses” was written just for them. But, to borrow from another Broadway hit, they may now be asking the District of South Carolina “Don’t Rain on My Parade.”

Not surprisingly, as our generic preemption scorecard reveals, generic plaintiffs are throwing anything and everything at the walls in the hope that something sticks. And, some courts have been more accommodating to them than others. The most recent decision to keep claims against generic manufacturers alive is Fisher v. Pelstring, C.A. No. 4:09-cv-00252-TLW, slip op. (D.S.C. Sept. 30, 2011). Due to our involvement in the metoclopramide litigation, we can’t offer extensive comment, but we can report what happened.

Please see full article below for more information.

LOADING PDF: If there are any problems, click here to download the file.

Topics:  Brand, FDA, Generic Drugs, Pharmaceutical

Published In: Civil Procedure Updates, Products Liability Updates

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Dechert LLP | Attorney Advertising

Don't miss a thing! Build a custom news brief:

Read fresh new writing on compliance, cybersecurity, Dodd-Frank, whistleblowers, social media, hiring & firing, patent reform, the NLRB, Obamacare, the SEC…

…or whatever matters the most to you. Follow authors, firms, and topics on JD Supra.

Create your news brief now - it's free and easy »